Vincerx Pharma, Inc. (VINC) Total Debt to Capital

Vincerx Pharma, Inc. (VINC) is developing innovative ADC drugs to combat hematological malignancies. The price chart confirms financial stability due to a lack of loans, while the individual debt-to-equity ratio stands at 0.00. The company's US laboratories are advancing small molecule therapies, testing them in top-tier clinics. Early-phase research results for lymphoma treatment are expected, while cost-cutting measures have already been priced in by investors.

Vincerx Pharma Inc. (VINC): Debt to Equity Ratio from 07/04/2022 to 05/31/2025

Metric breakdowns and analytics for Vincerx Pharma (VINC)

- share price and consensus valuation forecast:

Stock Price Vincerx Pharma Inc.|VINC - Consensus Target

- market capitalization details:

Market Capitalization Vincerx Pharma|VINC - Enterprise Value

- book capitalization indicators:

Net Assets per Single Share Vincerx Pharma|VINC - Accounting Capitalization|Market Capitalization to Book Value Ratio vincerx.com|VINC - Cumulative Company Assets

- debt and liquidity details:

- net income and valuation ratios data:

VINC - Company Net Income

Fundamental company valuation:Vincerx Pharma, Inc.

Finished products of Vincerx Pharma Inc.

For Vincerx Pharma, Inc. (VINC), which develops complex patent-protected oncology drugs, the d/e ratio (total debt-to-equity) reflects the balance between borrowed funds and equity assets. This metric compares total liabilities to equity, allowing investors to assess the degree of financial leverage and the risk of instability should the debt load grow excessively amid capital-intensive research and development.

Competitor analysis for Vincerx Pharma, Inc.